GTS Securities’s Dyne Therapeutics DYN Stock Holding History

GTS Securities’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-18,613	Closed	-$528K	–	4020
2024 Q1	$528K	Buy	+18,613	New	+$421K	﹤0.01%	2534

Other funds holding DYN

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GTS Securities's DYN Position: Q2 2024 in Review

GTS Securities sold out of Dyne Therapeutics (DYN) in Q2 2024, closing a stake of 18,613 shares — an estimated $528K sold.

GTS Securities first reported a position in DYN in Q1 2024 and held it in 1 quarter. The position peaked at $528K in Q1 2024. 193 funds tracked by Wall St. Rank hold DYN as of Q2 2024.

GTS Securities reported no remaining Dyne Therapeutics position as of Q2 2024 after selling out during the quarter.
GTS Securities sold 18,613 Dyne Therapeutics shares in Q2 2024, an estimated $528K.
GTS Securities first reported a position in Dyne Therapeutics in Q1 2024 and held it in 1 quarter.
GTS Securities's Dyne Therapeutics position peaked at $528K in Q1 2024.
193 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2024.

Based on GTS Securities's 13F filing for Q2 2024, filed 14 Aug 2024.